CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets


Change log
Authors
Bradley, Allan 
Abstract

Abstract: Human cancers harbor substantial genetic, epigenetic, and transcriptional changes, only some of which drive oncogenesis at certain times during cancer evolution. Identifying the cancer-driver alterations amongst the vast swathes of “passenger” changes still remains a major challenge. Transposon and CRISPR screens in vivo provide complementary methods for achieving this, and each platform has its own advantages. Here, we review recent major technological breakthroughs made with these two approaches and highlight future directions. We discuss how each genetic screening platform can provide unique insight into cancer evolution, including intra-tumoral heterogeneity, metastasis, and immune evasion, presenting transformative opportunities for targeted therapeutic intervention.

Description

Funder: Wellcome Trust; doi: http://dx.doi.org/10.13039/100004440


Funder: National Institute for Health Research; doi: http://dx.doi.org/10.13039/501100000272


Funder: prostate cancer research council

Keywords
Review, Cancer Evolution and Metastasis
Journal Title
Genome Biology
Conference Name
Journal ISSN
1474-760X
Volume Title
21
Publisher
BioMed Central